FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1: Name and Address of Reporting Issuer

Advanced Proteome Therapeutics Corporation (the "**Company**")
BioSquare, 650 Albany Street, Suite 113
Boston, Massachusetts 02118

Item 2: Date of Material Change

June 4, 2019.

Item 3: News Release

A New release was issued and disseminated on June 6, 2019 and filed on SEDAR (www.sedar.com).

Item 4: Summary of Material Changes

The Company announced that it has closed the first tranche of a non-brokered private placement (the "**Private Placement**") raising gross proceeds of $322,000 by the issuance of 3,220,000 units at a price of $0.10 per unit.

Item 5: Full Description of Material Change

The Company announced that it has closed the first tranche of the Private Placement raising gross proceeds of $322,000 by the issuance of 3,220,000 units at a price of $0.10 per unit.

Each unit consists of one common share and one-half of one transferable common share purchase warrant of the Company, with each whole warrant exercisable for a period of 12 months from the date of closing at a price of $0.15 per share.

The Company paid finder's fees ranging from 2% to 6% cash to Haywood Securities Inc. and Canaccord Genuity Corp. All securities issued in connection with the Private Placement are subject to a 4-month hold period in Canada.

The gross proceeds of the Private Placement will be used for funding of the Company's subsidiary for research and development activities related to the Company's site-selective linker technology for the development of antibody-drug conjugates and for general working capital.

The Company confirms that there is no material fact or material change about the Company that has not already been generally disclosed.

Insiders of the Company subscribed for 200,000 units, with Martin Woodward, a director of the Company, subscribing for 100,000 units and Kenneth Phillippe CFO of the Company, subscribing for 100,000 units. As a result, the Private Placement is a related party transaction (as defined under Multilateral Instrument 61-101 *Protection of Minority Security Holders in Special Transactions* ("**MI 61-101**")). The Company relied upon the "Issuer Not Listed on Specified Markets" and "Fair Market Value Not More Than $2,500,000" exemptions from the formal valuation and minority shareholder approval requirements, respectively, under MI 61-101.

About the Company

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity, and lower toxicity than other therapies that can also attack healthy cells. Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential. www.advancedproteome.com

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

None.

Item 8: Executive Officer

Paul Woodward
President and CEO
T: 604.690.3797

Item 9: Date of Report

June 6, 2019.